Seminars in Nuclear Medicine
Volume 35, Issue 2 , Pages 84-99 , April 2005

Evolving role of positron emission tomography in breast cancer imaging

  • William B. Eubank, MD

      Affiliations

    • Department of Radiology (S-113-RAD), Puget Sound VA Health Care System, Seattle, WA.
    • Corresponding Author InformationAddress reprint requests to William B. Eubank, MD, Department of Radiology (S-113-RAD), Puget Sound VA Health Care System, 1660 South Columbian Way, Seattle, WA 98108-1597.
    • ,
  • David A. Mankoff, MD, PhD

      Affiliations

    • Division of Nuclear Medicine, University of Washington School of Medicine, Seattle, WA.

References 

  1. Greenlee RT , Murray T , Bolden S , et al.   Cancer Statistics, 2000 . CA Cancer J Clin . 2000;50:7–33
  2. Hortobagyi GN . Developments in chemotherapy of breast cancer . Cancer . 2000;88(suppl 12):3073–3079
  3. Feldman LD , Hortobagyi GN , Buzdar AU , et al.   Pathological assessment of response to induction chemotherapy in breast cancer . Cancer Res . 1986;46:2578–2581
  4. Machiavelli MR , Romero AO , Pérez JE , et al.   Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma . Cancer J Sci Am . 1998;4:125–131
  5. Hortobagyi GN . Salvage chemotherapy for metastatic breast cancer . Semin Hematol . 1987;24:56–61
  6. Honig SH , Swain SM . Hormonal manipulation in the adjuvant treatment of breast cancer . In:  DeVita VT ,  Hellman S ,  Rosenberg SA editor. Important Advances in Oncology . Philadelphia, PA: JB Lippincott; 1993;p. 103–123
  7. Wakeling AE , Nicholson RI , Gee JM . Prospects for combining hormonal and nonhormonal growth factor inhibition . Clin Cancer Res . 2001;7(suppl 12):4350s–4355s discussion 4411s-4412s
  8. Husband JE . Monitoring tumor response . Eur Radiol . 1996;6:775–785
  9. Tannock IF , Hill RP . The Basic Science of Oncology . New York, NY: McGraw-Hill; 1992;
  10. Muehllehner G , Karp JS . Positron emission tomography imaging-technical considerations . Semin Nucl Med . 1986;16:35–50
  11. Hoffman EJ , van der Stee M , Ricci AR , et al.   Prospects for both precision and accuracy in positron emission tomography . Ann Neurol . 1984;15:S25–S34
  12. Eary JF , Mankoff DA . Tumor metabolic rates in sarcoma using FDG PET . J Nucl Med . 1998;39:250–254
  13. Warburg O . The Metabolism of Tumours . London, UK: Constable; 1930;
  14. Spence AM , Muzi M , Graham MM , et al.   Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]-glucose and FDG (Analysis of the FDG lumped constant) . J Nucl Med . 1998;39:440–448
  15. Adler LP , Crowe JP , Al-Kaisi NK , et al.   Evaluation of breast masses and axillary lymph nodes with [F-18]-2-deoxy-2-fluoro-D-glucose PET . Radiology . 1993;187:743–750
  16. Hoh CK , Hawkins RA , Glaspy JA , et al.   Cancer detection with whole-body PET using 2-[F-18]-fluoro-2-deoxy-D-glucose . J Comput Assist Tomog . 1993;17:582–589
  17. Avril N , Dose J , Janicke F , et al.   Metabolic characterization of breast tumors with positron emission tomography using [F-18]-fluorodeoxyglucose . J Clin Oncol . 1996;14:1848–1857
  18. Avril N , Rose CA , Schelling M , et al.   Breast imaging with positron emission tomography and [fluorine-18]-fluorodeoxyglucose (use and limitations) . J Clin Oncol . 2000;18:3495–3502
  19. Schirrmeister H , Kuhn T , Guhlmann A , et al.   [F-18]-2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer (Comparison with the standard staging procedures) . Eur J Nucl Med . 2001;28:351–358
  20. Scheidhauer K , Scharl A , Pietrzyk U , et al.   Qualitative [18F]-FDG positron emission tomography in primary breast cancer (Clinical relevance and practicability) . Eur J Nucl Med . 1996;23:618–623
  21. Parker SH , Jobe WE . Large-core breast biopsy offers reliable diagnosis . Diagnostic Imaging . 1990;12:90–97
  22. Orel SG , Schnall MD , Powell CM , et al.   Staging of suspected breast cancer (Effect of MR imaging and MR-guided biopsy) . Radiology . 1995;196:115–122
  23. Weinberg I , Majewski S , Weisenberger A , et al.   Preliminary results for positron emission mammography (Real-time functional breast imaging in a conventional mammography gantry) . Eur J Nucl Med . 1996;23:804–806
  24. Murthy K , Aznar M , Thompson CJ , et al.   Results of preliminary clinical trials of the positron emission mammography system PEM-I (A dedicated breast imaging system producing glucose metabolic images using FDG) . J Nucl Med . 2000;41:1851–1858
  25. Murthy K , Aznar M , Bergman AM , et al.   Positron emission mammographic instrument (Initial results) . Radiology . 2000;215:280–285
  26. Adler LP , Weinberg IN , Bradbury MS , et al.   Method for combined FDG-PET and radiographic imaging of primary breast cancers . Breast J . 2003;9:163–166
  27. Mankoff DA . Are we ready for dedicated breast imaging approaches? . J Nucl Med . 2003;44:594–595 (invited commentary)
  28. Crippa F , Seregni E , Agresti R , et al.   Association between [18F]-fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer (a preliminary observation) . Eur J Nucl Med . 1998;25:1429–1434
  29. Oshida M , Uno K , Suzuki M , et al.   Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose . Cancer . 1998;82:2227–2234
  30. Avril N , Menzel M , Dose J , et al.   Glucose metabolism of breast cancer assessed by 18F-FDG PET (histologic and immunohistochemical tissue analysis) . J Nucl Med . 2001;42:9–16
  31. Bos R , van Der Hoeven JJ , van Der Wall E , et al.   Biologic correlates of [18F]-fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography . J Clin Oncol . 2002;20:379–387
  32. Mankoff DA , Dunnwald LK , Gralow JR , et al.   Blood flow and metabolism in locally advanced breast cancer (LABC) (Relationship to response to therapy) . J Nucl Med . 2002;43:500–509
  33. Buck A , Schirrmeister H , Kuhn T , et al.   FDG uptake in breast cancer (Correlation with biological and clinical prognostic parameters) . Eur J Nucl Med Mol Imaging . 2002;29:1317–1323
  34. Dehdashti F , Mortimer JE , Siegel BA , et al.   Positron tomographic assessment of estrogen receptors in breast cancer (Comparison with FDG-PET and in vitro receptor assays) . J Nucl Med . 1995;36:1766–1774
  35. Crippa F , Agresti R , Seregni E , et al.   Prospective evaluation of [fluorine-18]-FDG PET in presurgical staging of the axilla in breast cancer . J Nucl Med . 1998;39:4–8
  36. Hockenberry D . Defining apoptosis . Am J Pathol . 1995;146:16–19
  37. Mathapala SP , Rempel A , Pederson PL . Aberrant glycolytic metabolism of cancer cells (A remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase) . J Bioenerg Biomembr . 1997;29:339–343
  38. Brand K . Aerobic glycosis by proliferating cells (Protection against oxidative stress at the expense of energy yield) . J Bioenerg Biomembr . 1997;29:335–364
  39. Gottleib E , Heiden MV , Thompson CB . Bcl-xL prevents the initial disease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor alpha-induced apoptosis . Molecular Cellular Biol . 2000;20:5680–5689
  40. West KA , Castillo SS , Dennis PA . Activation of the PI3K/Akt pathway and chemotherapeutic resistance . Drug Resist Update . 2002;6:234–248
  41. Inoue T , Yutani K , Taguchi T , et al.   Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography . J Cancer Res Clin Oncol . 2004;130:273–278
  42. Mankoff DA , Dehdashti F , Shields AF . Characterizing tumors using metabolic imaging (PET imaging of cellular proliferation and steroid receptors) . Neoplasia . 2000;2:71–88
  43. Rasey JS , Koh WJ , Evans ML , et al.   Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]-fluoromisonidazole (A pretherapy study of 37 patients) . Int J Radiat Oncol Biol Phys . 1996;36:417–428
  44. Adler LP , Faulhaber PF , Schnur KC , et al.   Axillary lymph node metastases (Screening with [F-18]-2-deoxy-2-fluoro-D- glucose (FDG) PET) . Radiology . 1997;203:323–327
  45. Utech CI , Young CS , Winter PF . Prospective evaluation of [fluorine-18]-fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry . Eur J Nucl Med . 1996;23:1588–1593
  46. Avril N , Dose J , Janicke F , et al.   Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-[fluorine-18]-fluoro-2-deoxy-D-glucose . J Natl Cancer Inst . 1996;88:1204–1209
  47. Smith IC , Ogston KN , Whitford P , et al.   Staging of the axilla in breast cancer (Accurate in vivo assessment using positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy- D-glucose) . Ann Surg . 1998;228:220–227
  48. Greco M , Crippa F , Agresti R , et al.   Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D- glucose-positron emission tomography (Clinical evaluation and alternative management) . J Natl Cancer Inst . 2001;93:630–635
  49. Wahl RL , Siegel BA , Coleman RE , et al.   Prospective multi-center study of axillary nodal staging with FDG positron emission tomography in breast cancer . J Clin Oncol . 2004;22:277–285
  50. Lovrics PJ , Chen V , Coates G , et al.   A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer . Ann Surg Oncol . 2004;11:846–853
  51. Silverstein MJ , Gierson ED , Waisman JR , et al.   Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? . Cancer . 1994;73:664–667
  52. Yeatman TJ , Cox CE . The significance of breast cancer lymph node micrometastases . Surg Oncol Clin N Am . 1999;8:481–496
  53. Albertini JJ , Lyman GH , Cox C , et al.   Lymphatic mapping and sentinel node biopsy in the patient with breast cancer . JAMA . 1996;276:1818–1822
  54. Barranger E , Grahek D , Antoine M , et al.   Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer . Ann Surg Oncol . 2003;10:622–627
  55. van der Hoeven JJ , Hoekstra OS , Comans EF , et al.   Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer . Ann Surg . 2002;236:619–624
  56. Guller U , Nitzsche EU , Schirp U , et al.   Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose (not yet!) . Breast Cancer Res Treat . 2002;71:171–173
  57. Yang JH , Nam SJ , Lee TS , et al.   Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients . Jpn J Clin Oncol . 2001;31:1–6
  58. Kelemen PR , Lowe V , Phillips N . Positron emission tomography and sentinel lymph node dissection in breast cancer . Clin Breast Cancer . 2002;3:73–77
  59. Fehr MK , Hornung R , Varga Z , et al.   Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy . Breast J . 2004;10:89–93
  60. Zornoza G , Garcia-Velloso MJ , Sola J , et al.   18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer . Eur J Surg Oncol . 2004;1:15–19
  61. Wagner JD , Schauwecker D , Davidson D , et al.   Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy . J Clin Oncol . 1999;17:1508–1515
  62. Wojcik C , Yahonda A , McFarlane D , et al.   Economic analysis of sentinel-node surgery versus preoperative FDG-PET in the management of patients with intermediate thickness cutaneous melanomas . J Nucl Med . 1997;38:34P; (abstract)
  63. Eubank WB , Mankoff DA , Schmiedl UP , et al.   Imaging of oncologic patients (benefit of combined CT and [F-18]-fluorodeoxyglucose positron emission tomography scan interpretation in the diagnosis of malignancy) . AJR . 1998;171:1103–1110
  64. Katz A , Strom EA , Buchholz TA , et al.   Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy (Implications for postoperative irradiation) . J Clin Oncol . 2000;18:2817–2827
  65. Hathaway PB , Mankoff DA , Maravilla KR , et al.   The value of combined FDG-PET and magnetic resonance imaging in the evaluation of suspected recurrent local-regional breast cancer (Preliminary experience) . Radiology . 1998;210:807–814
  66. Ahmad A , Barrington S , Maisey M , et al.   Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients . Br J Cancer . 1999;79:478–482
  67. Donegan WL . The influence of untreated internal mammary metastases upon the course of mammary cancer . Cancer . 1977;39:533–538
  68. Cody HS , Urban JA . Internal mammary node status (a major prognosticator in axillary node- negative breast cancer) . Ann Surg Oncol . 1995;2:32–37
  69. Sugg SL , Ferguson DJ , Posner MC , et al.   Should internal mammary nodes be sampled in the sentinel lymph node era? . Ann Surg Oncol . 2000;7:188–192
  70. Bellon JR , Gralow JR , Livingston RB , et al.   Evaluation of the internal mammary (IM) lymph nodes by FDG-PET in locally advanced breast cancer (LABC) . Am J Clinical Oncol . 2004;27:407–410
  71. Bernstein V , Jones A , Mankoff DA , et al.   Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission (FDG PET) in medial hemisphere breast cancer . J Nucl Med . 2000;41:289P; (abstract)
  72. Vansteenkiste JF , Stroobants SG , De Leyn PR , et al.   Lymph node staging in non-small-cell lung cancer with FDG-PET scan (A prospective study on 690 lymph node stations from 68 patients) . J Clin Oncol . 1998;16:2142–2149
  73. Scott WJ , Gobar LS , Terry JD , et al.   Mediastinal lymph node staging of non-small-cell lung cancer (a prospective comparison of computed tomography and positron emission tomography) . J Thorac Cardiovasc Surg . 1996;111:642–648
  74. Eubank WB , Mankoff DA , Takasugi J , et al.   18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer . J Clin Oncol . 2001;19:3516–3523
  75. Moon DH , Maddahi J , Silverman DHS , et al.   Accuracy of whole-body [fluorine-18]-FDG PET for the detection of recurrent or metastatic breast carcinoma . J Nucl Med . 1998;39:431–435
  76. Bender H , Kirst J , Palmedo H , et al.   Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma . Anticancer Res . 1997;17:1687–1692
  77. Lonneux M , Borbath I , Berliere M , et al.   The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer . Clinical Positron Imaging . 2000;3:45–49
  78. Kim TS , Moon WK , Lee DS , et al.   Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer . World J Surg . 2001;25:829–834
  79. Siggelkow W , Zimny M , Faridi A , et al.   The value of positron emission tomography in the follow-up for breast cancer . Anticancer Res . 2003;23:1859–1867
  80. Danforth DN , Aloj L , Carrasquillo JA , et al.   The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer . Breast Cancer Res Treat . 2002;75:135–146
  81. Kamel EM , Wyss MT , Fehr MK , et al.   [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer . J Cancer Res Clin Oncol . 2003;129:147–153
  82. Liu CS , Shen YY , Lin CC , et al.   Clinical impact of [18F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels (A preliminary report) . Jpn J Clin Oncol . 2002;32:244–247
  83. Gallowitsch HJ , Kresnik E , Gasser J , et al.   F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma (A comparison to conventional imaging) . Invest Radiol . 2003;38:250–256
  84. Suarez M , Perez-Castejon MJ , Jimenez A , et al.   Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers . Q J Nucl Med . 2002;46:113–121
  85. Vranjesevic D , Filmont JE , Meta J , et al.   Whole-body 18F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients . J Nucl Med . 2002;43:325–329
  86. Nielsen OS , Munro AJ , Tannock IF . Bone metastases (pathophysiology and management policy) . J Clin Oncol . 1991;9:509–524
  87. Cook GJ , Houston S , Rubens R , et al.   Detection of bone metastases in breast cancer by 18FDG PET (Differing metabolic activity in osteoblastic and osteolytic lesions) . J Clin Oncol . 1998;16:3375–3379
  88. Schirrmeister H , Guhlmann A , Kotzerke J , et al.   Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography . J Clin Oncol . 1999;17:2381–2389
  89. Schirrmeister H , Glatting G , Hetzel J , et al.   Prospective evaluation of the clinical value of planar bone scans, SPECT, and [18]F-labeled NaF PET in newly diagnosed lung cancer . J Nucl Med . 2001;42:1800–1804
  90. Yap CS , Seltzer MA , Schieppers C , et al.   Impact of whole-body 18FDG PET on staging and managing patients with breast cancer (The referring physician’s perspective) . J Nucl Med . 2001;42:1334–1337
  91. Eubank WB , Mankoff DA , Bhattacharya M , et al.   Impact of [F-18]-Fluorodeoxyglucose PET on defining the extent of disease and management of patients with recurrent or metastatic breast cancer . Am J Roentgenol . 2004;83:479–486
  92. van Oost FJ , van der Hoeven JJ , Hoekstra OS , et al.   Staging in patients with locoregionally recurrent breast cancer (Current practice and prospects for positron emission tomography) . Eur J Cancer . 2004;40:1545–1553
  93. Helvie MA , Joynt LK , Cody RL , et al.   Locally advanced breast carcinoma (Accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy) . Radiology . 1996;198:327–332
  94. Wahl RL , Zasadny K , Helvie MA , et al.   Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography (initial evaluation) . J Clin Oncol . 1993;11:2101–2111
  95. Bassa P , Kim EE , Inoue T , et al.   Evaluation of preoperative chemotherapy using PET with [fluorine-18]-fluorodeoxyglucose in breast cancer . J Nucl Med . 1996;37:931–938
  96. Jansson T , Westlin J , Ahlstrom H , et al.   Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer (A method for early therapy evaluation?) . J Clin Oncol . 1995;13:1470–1477
  97. Schelling M , Avril N , Nahrig J , et al.   Positron emission tomography using [18F]-fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer . J Clin Oncol . 2000;18:1689–1695
  98. Smith IC , Welch AE , Hutcheon AW , et al.   Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy . J Clin Oncol . 2000;18:1676–1688
  99. Jain RK . Haemodynamic and transport barriers to the treatment of solid tumors . Int J Radiat Biol . 1991;60:85–100
  100. Mankoff DA , Dunnwald LK , Gralow JR , et al.   Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy . J Nucl Med . 2003;44:1806–1814
  101. Gennari A , Donati S , Salvadori B , et al.   Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients . Clin Breast Cancer . 2000;1:156–161
  102. Schneider JA , Divgi CR , Scott AM , et al.   Flare on bone scintigraphy following taxol chemotherapy for metastatic breast cancer . J Nucl Med . 1994;35:1748–1752
  103. Vogel C , Schoenfelder J , Shemano I , et al.   Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer . J Clin Oncol . 1995;13:1123–1128
  104. Stafford SE , Gralow JR , Schubert EK , et al.   Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy . Acad Radiol . 2002;9:913–921
  105. Mortimer JE , Dehdashti F , Siegel BA , et al.   Metabolic flare (Indicator of hormone responsiveness in advanced breast cancer) . J Clin Oncol . 2001;19:2797–2803
  106. Kaklamani V , O’Regan RM . New targeted therapies in breast cancer . Semin Oncol . 2004;31:20–25
  107. Katzenellenbogen JA , Welch MJ , Dehdashti F . The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer . Anticancer Res . 1997;17:1573–1576
  108. Gonzalez-Trotter DE , Manjeshwar RM , Doss M , et al.   Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner . J Nucl Med . 2004;45:1237–1244
  109. Wilson CBJH , Lammertsma AA , McKenzie CG , Sikora K , Jones T . Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography (A rapid and non-invasive dynamic method) . Cancer Res . 1992;52:1592–1597
  110. Zasadny KR , Tatsumi M , Wahl RL . FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers . Eur J Nucl Med Mol Imaging . 2003;30:274–280
  111. Buck AK , Schirrmeister H , Mattfeldt T , et al.   S. N. Biological characterisation of breast cancer by means of PET . Eur J Nucl Med Mol Imaging . 2004;31(suppl 1):S80–S87
  112. Haubner R , Wester HJ , Burkhart F , et al.   Glycosylated RGD-containing peptides (Tracer for tumor targeting and angiogenesis imaging with improved biokinetics) . J Nucl Med . 2001;42:326–336
  113. Chen X , Park R , Tohme M , et al.   MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide . Bioconjug Chem . 2004;15:41–49
  114. Zheng QH , Fei X , Liu X , et al.   Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents . Nucl Med Biol . 2002;29:761–770
  115. Jagoda EM , Aloj L , Seidel J , et al.   Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts . Mol Imaging Biol . 2002;4:369–379
  116. Berger F , Gambhir SS . Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects (applications to breast cancer) . Breast Cancer Res . 2001;3:28–35
  117. McGuire W , Horwitz K . Predicting response to endocrine therapy in human breast cancer (A hypothesis) . Science . 1975;189:726–727
  118. Sledge GJ , McGuire W . Steroid hormone receptors in human breast cancer . Adv Cancer Res . 1983;38:61–75
  119. McGuire W , Horwitz K . Predicting response to endocrine therapy in human breast cancer (A hypothesis) . Science . 1975;189:726–727
  120. Sledge GJ , McGuire W . Steroid hormone receptors in human breast cancer . Adv Cancer Res . 1983;38:61–75
  121. Seimbelle Y , Rousseau J , Benard F , et al.   18F-labeled difluoroestrodiols (preparation and preclinical evaluation as estrogen receptor-binding radiopharmaeceuticals) . Steroids . 2002;67:765–775
  122. Kiesewetter DO , Kilbourn MR , Landvatter SW , et al.   Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissue of immature rats . J Nucl Med . 1984;25:1212–1221
  123. Mintun MA , Welch MJ , Siegel BA , et al.   Breast cancer (PET imaging of estrogen receptors) . Radiology . 1988;169:45–48
  124. Mankoff DA , Peterson LM , Petra PH , et al.   Factors affecting the level and heterogeneity of uptake of [18F]Fluoroestradiol (FES) in patients with estrogen receptor positive (ER+) breast cancer . J Nucl Med . 2002;43:287P; (abstract)
  125. McGuire AH , Dehdashti F , Siegel BA , et al.   Positron tomographic assessment of 16alpha-[F-18]-fluoro-17beta-estradiol uptake in metastatic breast carcinoma . J Nucl Med . 1991;32:1526–1531
  126. Mankoff DA , Peterson LM , Tewson TJ , et al.   [18F]-fluoroestradiol radiation dosimetry in human PET studies . J Nucl Med . 2001;42:679–684
  127. Mankoff DA , Peterson LM , Tewson TJ , et al.   Non-invasive PET imaging of ER expression in breast cancer (Sex steroid binding protein (SBP or SHBG) interaction and ER expression heterogeneity) . Proc AACR . 2001;42:6; (abstract)
  128. Campbell FC , Blamey RW , Elston CW , et al.   Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy . Lancet . 1981;1:1317–1319
  129. Dehdashti F , Flanagan FL , Mortimer JE , et al.   Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy . Eur J Nucl Med . 1999;26:51–56
  130. Mankoff DA , Peterson LM , Stekhova S , et al.   Uptake of [F-18]-Fluoroestradiol (FES) predicts response of recurrent or metastatic breast cancer to hormonal therapy . J Nucl Med . 2003;44:126P; (abstract)
  131. Inoue T , Kim EE , Wallace S , et al.   Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer (Preliminary study) . Cancer Biother Radiopharm . 1996;11:235–245
  132. Seimbille Y , Benard F , Rousseau J , et al.   Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16alpha-position of fulvestrant . (faslodex; ICI 182,780) Nucl Med Biol . 2004;31:691–698
  133. Brust P , Rodig H , Romer J , et al.   Distribution of 16alpha-[18F]fluoro-estradiol-3,17beta-disulfamate in rats, tumour-bearing mice and piglets . Appl Radiat Isot . 2002;57:687–695
  134. Aliaga A , Rousseau JA , Ouellette R , et al.   Breast cancer models to study the expression of estrogen receptors with small animal PET imaging . Nucl Med Biol . 2004;31:761–770
  135. Dowsett M , Harper-Wynne C , Boeddinghaus I , et al.   HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer . Cancer Res . 2001;61:8452–8458
  136. Kaye SB . Multidrug resistance (clinical relevance in solid tumours and strategies for circumvention) . Curr Opin Oncol . 1998;10(suppl 1):S15–S19
  137. Dolan ME , Pegg AE . O6-benzylguanine and its role in chemotherapy . Clin Cancer Res . 1997;3:837–847
  138. Sutherland RM . Tumor hypoxia and gene expression—implications for malignant progression and therapy . Acta Oncol . 1998;37:567–574
  139. Teicher BA . Hypoxia and drug resistance . Cancer Metastasis Rev . 1994;13:139–168
  140. Rasey JS , Koh W , Grierson JR , et al.   Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia . Int J Radiat Oncol Biol Phys . 1989;17:985–991
  141. Hendrikse NH , de Vries EG , Eriks-Fluks L , et al.   A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier . Cancer Res . 1999;59:2411–2416
  142. Ciarmiello A , Vecchio SD , Silvestro P , et al.   Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer . J Clin Oncol . 1998;16:1677–1683
  143. Zheng QH , Liu X , Fei X , et al.   Synthesis and preliminary biological evaluation of radiolabeled O6-benzylguanine derivatives, new potential PET imaging agents for the DNA repair protein O6-alkylguanine-DNA alkyltransferase in breast cancer . Nucl Med Biol . 2003;30:405–415
  144. Aboagye EO , Price PM . Use of positron emission tomography in anticancer drug development . Invest New Drugs . 2003;21:169–181
  145. Vaupel P , Hockel M . Oxygenation status of breast cancer (The Mainz experience) . In:  Vaupel P , Kelleher  editor. Tumor Hypoxia . Stuttgart, Germany: Wissenschaftliche Veragsgesellschaft mbH; 1999;p. 1–11
  146. Clavo AC , Wahl RL . Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells . J Nucl Med . 1996;37:502–506
  147. Rajendran JG , Mankoff DA , O’Sullivan F , et al.   Hypoxia and glucose metabolism in malignant tumors (Evaluation by FMISO and FDG PET imaging) . Clin Cancer Res . 2004;10:2245–2252
  148. Rajendran JG , Krohn KA . Imaging tumor hypoxia . In:  Bailey DL ,  Townsend DW ,  Valk PE ,  Maisey MN editor. Positron Emission Tomography (Principles and Practice) . London, UK: Springer Verlag; 2002;p. 689–696
  149. Dehdashti F , Grigsby PW , Mintun MA , et al.   Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM (Relationship to therapeutic response-a preliminary report) . Int J Radiat Oncol Biol Phys . 2003;55:1233–1238
  150. Piwnica-Worms D , Chiu ML , Budding M , et al.   Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex . Cancer Res . 1993;53:977–984
  151. Mankoff DA , Dunnwald LK , Gralow JR , et al.   [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow . Nucl Med Biol . 2002;29:719–727
  152. Muzi M , Link JM , Mankoff DA , et al.   Quantitative estimation of P-glycoprotein transport using [C-11]-verapamil . J Nucl Med . 2003;44:365P
  153. Tannock IF . Cell proliferation . In:  Tannock IF ,  Hill RP editor. The Basic Science of Oncology . New York, NY: McGraw-Hill; 1992;p. 154–157
  154. Cleaver JE . Thymidine metabolism and cell kinetics . Frontiers Biol . 1967;6:43–100
  155. Livingston RB , Hart JS . The clinical applications of cell kinetics in cancer therapy . Annu Rev Toxicol . 1977;17:529–543
  156. Shields AF , Mankoff DA , Link JM , et al.   [Carbon-11]-thymidine and FDG to measure therapy response . J Nucl Med . 1998;39:1757–1762
  157. Shields AJ , Grierson J , Dohmen BM , et al.   Imaging proliferation in vivo with [F-18]FLT and positron emission tomography . Nat Med . 1998;4:1334–1336
  158. Grierson JR , Shields AF . Radiosynthesis of 3′-deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT for imaging of cellular proliferation in vivo) . Nucl Med Biol . 2000;27:143–156
  159. Mankoff DA , Shields AF , Krohn KA . PET imaging of cellular prroliferation . Radiol Clin North Am . 2005;43:153–168
  160. Smyczek-Gargya B , Fersis N , Dittmann H , et al.   PET with [18F]fluorothymidine for imaging of primary breast cancer (A pilot study) . Eur J Nucl Med Mol Imaging . 2004;31:720–724
  161. Pio BS , Park CK , Satyamurthy  , et al.   PET with Fluoro-L-thymidine allows early prediction of breast cancer response to chemotherapy . J Nucl Med . 2003;44:76P; (abstract)
  162. Wells P , Aboagye E , Gunn RN , et al.   2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337 . J Natl Cancer Inst . 2003;95:675–682
  163. Kaklamani VG , Gradishar WJ . Role of capecitabine (Xeloda) in breast cancer . Expert Rev Anticancer Ther . 2003;3:137–144
  164. Blankenberg F , Ohtsuki K , Strauss HW . Dying a thousand deaths. Radionuclide imaging of apoptosis . Q J Nucl Med . 1999;43:170–176
  165. Zijlstra S , Gunawan J , Burchert W . Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET . Appl Radiat Isot . 2003;58:201–207
  166. Yagle KJ , Eary JF , Tait JF , et al.   Evaluation of [F-18]-annexin V as a PET imaging agent in an animal model of apoptosis . 2004; (submitted)

 Supported in part by NIH grants RO1CA42045, RO1CA72064, RO1CA90771, and S10RR177229.

PII: S0001-2998(04)00073-X

doi: 10.1053/j.semnuclmed.2004.11.001

Seminars in Nuclear Medicine
Volume 35, Issue 2 , Pages 84-99 , April 2005

Article Tools

* Image Usage & Resolution